Details of the Drug

General Information of Drug (ID: DM7MT6E)

• Drug Name: Prasugrel
• Synonyms: Effient (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1], [2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 373.4
  Topological Polar Surface Area (xlogp); 3.6
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Elimination: 1% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7.4 hours [4]
  Metabolism: The drug is metabolized via the human carboxylesterase (hCE) 2 [5]
  Vd: The volume of distribution (Vd) of drug is 44-68 L [6]
• Chemical Identifiers:
  Formula: C20H20FNO3S
  IUPAC Name: [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
  Canonical SMILES: CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
  InChI: InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
  InChIKey: DTGLZDAWLRGWQN-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 6918456
  ChEBI ID: CHEBI:87723
  CAS Number: 150322-43-3
  DrugBank ID: DB06209
  TTD ID: D07IRF
  INTEDE ID: DR1326
  ACDINA ID: D00547

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]
Cytochrome P450 2B6 (CYP2B6) Main DME	DEPKLMQ	CP2B6_HUMAN	Substrate	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prasugrel

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Prasugrel and Vorapaxar.	Myocardial infarction [BA41-BA43]	[49]

Coadministration of a Drug Treating the Disease Different from Prasugrel (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Altered absorption of Prasugrel due to GI dynamics variation caused by Oliceridine.	Acute pain [MG31]	[50]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Prasugrel and Levomilnacipran.	Chronic pain [MG30]	[51]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Prasugrel and Regorafenib.	Colorectal cancer [2B91]	[52]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Prasugrel and Intedanib.	Colorectal cancer [2B91]	[53]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Prasugrel and Ardeparin.	Coronary thrombosis [BA43]	[54]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Prasugrel and Danaparoid.	Deep vein thrombosis [BD71]	[54]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Prasugrel and Rivaroxaban.	Deep vein thrombosis [BD71]	[55]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Prasugrel and Vilazodone.	Depression [6A70-6A7Z]	[51]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Prasugrel and Vortioxetine.	Depression [6A70-6A7Z]	[51]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Prasugrel and Desvenlafaxine.	Depression [6A70-6A7Z]	[51]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Prasugrel and Apigenin.	Discovery agent [N.A.]	[56]
Tazemetostat	DMWP1BH	Major	Increased risk of bleeding by the combination of Prasugrel and Tazemetostat.	Follicular lymphoma [2A80]	[52]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Prasugrel and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[52]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Prasugrel and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[57]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Prasugrel and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[58]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Prasugrel and Ibrutinib.	Mature B-cell lymphoma [2A85]	[50]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Prasugrel and Ponatinib.	Mature B-cell lymphoma [2A85]	[59]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Prasugrel and Panobinostat.	Multiple myeloma [2A83]	[60]
Fedratinib	DM4ZBK6	Major	Increased risk of bleeding by the combination of Prasugrel and Fedratinib.	Myeloproliferative neoplasm [2A20]	[52]
Ruxolitinib	DM7Q98D	Major	Increased risk of bleeding by the combination of Prasugrel and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[52]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Prasugrel and Nepafenac.	Osteoarthritis [FA00-FA05]	[61]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Prasugrel and MK-4827.	Ovarian cancer [2C73]	[52]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Prasugrel and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[62]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Prasugrel and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[63]
Plicamycin	DM7C8YV	Major	Increased risk of bleeding by the combination of Prasugrel and Plicamycin.	Testicular cancer [2C80]	[52]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Prasugrel and Apixaban.	Thrombosis [DB61-GB90]	[52]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Prasugrel and Brilinta.	Thrombosis [DB61-GB90]	[52]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Prasugrel and Cabozantinib.	Thyroid cancer [2D10]	[64]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Prasugrel and Betrixaban.	Venous thromboembolism [BD72]	[65]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucrose stearate	E00502	9898327	Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Haematite red	E00236	14833	Colorant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Prasugrel 10 mg tablet	10 mg	Oral Tablet	Oral
Prasugrel 5 mg tablet	5 mg	Oral Tablet	Oral
Prasugrel Hydrochloride eq 10mg base tablet	eq 10mg base	Tablet	Oral
Prasugrel Hydrochloride eq 5mg base tablet	eq 5mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562).
• [2] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [6] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [7] The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
• [8] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [9] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [10] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [11] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [12] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [13] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [14] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [15] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [18] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [19] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [20] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [21] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [22] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [23] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [24] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [25] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [26] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [27] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [28] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [29] Drugs that may have potential CYP2B6 interactions.
• [30] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [31] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [32] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [33] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [34] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [35] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [36] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [37] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [38] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [39] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [40] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [41] P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
• [42] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
• [44] Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
• [45] Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
• [46] Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
• [47] Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
• [48] Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8.
• [49] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [50] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [51] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [52] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [53] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [54] Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
• [55] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [56] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
• [57] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
• [58] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [59] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [60] Cerner Multum, Inc. "Australian Product Information.".
• [61] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [62] Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
• [63] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
• [64] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [65] Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.